Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling

Investigational New Drugs

Volumn 30, Issue 6, 2012, Pages 2252-2262

  Zanotto Filho, Alfeu ^a,c   Braganhol, Elizandra ^a,b   Oliveira Battastini, Ana Maria ^a   Fonseca Moreira, José Cludio ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

^c Instituto de Ciencias Biologicas e da Saude Pontifical Catholic University of Minas Gerais   (Brazil)

Author keywords

Apoptosis; Chemotherapy; Glioblastoma; MG132

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 3; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL XL; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE 1;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; CANCER CELL; CELL MEMBRANE DEPOLARIZATION; CELL VIABILITY; CHROMATIN CONDENSATION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; GLIOBLASTOMA; HUMAN; HUMAN CELL; MITOCHONDRIAL PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ADJUVANTS, PHARMACEUTIC; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DOXORUBICIN; GLIOBLASTOMA; HUMANS; LEUPEPTINS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEASOME INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; SIGNAL TRANSDUCTION;

EID: 84875539389     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9804-z     Document Type: Article

References (46)

1. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Pro-teasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622
2. Baiz D, Pozzato G, Dapas B, Farra R, Scaggiante B, Grassi M, Uxa L, Giansante C, Zennaro C, Guarnieri G, Grassi G (2009) Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie 91:373-382. doi:10.1016/j.biochi. 2008.10.015
3. Braganhol E, Zamin LL, Cañedo AD, Horn F, Tamajusuku AS, Wink MR, Salbego C, Battastini AM (2006) Antiproliferative effect of quercetin in the human U138MG glioma cell line. Antican-cer Drugs 17:663-671. doi:10.1097/01.cad.0000215063.23932.02
4. Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC, Sikic BI (2006) Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol 24:274-287. doi:10.1200/JCO.2005.02.9405
5. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E (2009) Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4:e7752. doi:10.1371/journal. pone.0007752
6. Brown RE, Law A (2006) Morphoproteomic demonstration of constitutive nuclear factor-kappaB activation in glioblastoma mul-tiforme with genomic correlates and therapeutic implications. Ann Clin Lab Sci 36:421-426
7. Bubici C, Papa S, Pham CG, Zazzeroni F, Franzoso G (2006) The NF-kappaB-mediated control of ROS and JNK signaling. Histol Histopathol 21:69-80
8. Chari A, Mazumder A, Jagannath S (2010) Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics 4:273-287. doi:10.2147/BTT.S3419
9. da Frota ML, Braganhol E, Canedo AD, Klamt F, Apel MA, Mothes B, Lerner C, Battastini AM, Henriques AT, Moreira JC (2009) Brazilian marine sponge Polymastia janeirensis induces apoptotic cell death in human U138MG glioma cell line, but not in a normal cell culture. Invest New Drugs 27:13-20. doi:10.1007/s10637-008-9134-3
10. Dhandapani KM, Mahesh VB, Brann DWJ (2007) Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem 102:522-538. doi:10.1111/j.1471-4159.2007.04633.x
11. Foti C, Florean C, Pezzutto A, Roncaglia P, Tomasella A, Gustincich S, Brancolini C (2009) Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system. Mol Cancer Ther 8:3140-3150. doi:10.1158/1535-7163. MCT-09-0431
12. Frankel A, Man S, Elliott P, Adams J, Kerbel RS (2000) Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 6:3719-3728
13. Jiang Z, Zheng X, Rich KM (2003) Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death. J Neurochem 84:273-281. doi:10.1046/j.1471-4159.2003.01522.x
14. Kasuga C, Ebata T, Kayagaki N, Yagita H, Hishii M, Arai H, Sato K, Okumura K (2004) Sensitization of human glioblastomas to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by NF-kappaB inhibitors. Cancer Sci 95:840-844. doi:10.1111/j.1349-7006.2004.tb02191.x
15. Kitagawa H, Tani E, Ikemoto H, Ozaki I, Nakano A, Omura S (1999) Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells. FEBS Lett 443:181-186. doi:10.1016/S0014-5793(98)01709-8
16. Klamt F, Shacter E (2005) Taurine chloramine, an oxidant derived from neutrophils, induces apoptosis in human B lymphoma cells through mitochondrial damage. J Biol Chem 280:21346-21352. doi:10.1074/jbc.M501170200
17. Ko BS, Chang TC, Chen CH, Liu CC, Kuo CC, Hsu C, Shen YC, Shen TL, Golubovskaya VM, Chang CC, Shyue SK, Liou JY (2010) Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Life Sci 86:199-206. doi:10.1016/j.lfs.2009.12.003
18. Koschny R, Holland H, Sykora J, Haas TL, Sprick MR, Ganten TM, Krupp W, Bauer M, Ahnert P, Meixensberger J, Walczak H (2007) Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 13:3403-3412. doi:10.1158/1078-0432.CCR-07-0251
19. La Ferla-Brühl K, Westhoff MA, Karl S, Kasperczyk H, Zwacka RM, Debatin KM, Fulda S (2007) NF-kappaB-independent sensi-tization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition. Oncogene 26:571-582. doi:10.1038/sj. onc.1209841
20. Lauricella M, Emanuele S, D'Anneo A, Calvaruso G, Vassallo B, Carlisi D, Portanova P, Vento R, Tesoriere G (2006) JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways. Apoptosis 11:607-625. doi:10.1007/s10495-006-4689-y
21. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM, Perez-Soler R (2003) Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9:1145-1154
22. Lu G, Punj V, Chaudhary PM (2008) Proteasome inhibitor Bortezo-mib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. Cancer Biol Ther 7: 603-608. doi: http://dx.doi.org/10.4161/cbt.7.4.5564
23. Mercer RW, Tyler MA, Ulasov IV, Lesniak MS (2009) Targeted therapies for malignant glioma: progress and potential. BioDrugs 23:25-35. doi:10.2165/00063030-200923010-00003
24. Monticone M, Biollo E, Fabiano A, Fabbi M, Daga A, Romeo F, Maffei M, Melotti A, Giaretti W, Corte G, Castagnola P (2009) z-Leucinyl-leucinyl- norleucinal induces apoptosis of human glioblastoma tumor-initiating cells by proteasome inhibition and mitotic arrest response. Mol Cancer Res 7:1822-1834. doi:10.1158/1541-7786.MCR-09-0225
25. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ (1998) Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95:5724-5729
26. Nakanishi C, Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5:297-309. doi:10.1038/nrc1588
27. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, Fulda S (2008) Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor-and drug-induced apoptosis. Cancer Res 68:6271-6280. doi:10.1158/0008-5472.CAN-07-6769
28. Phuphanich S, Supko JG, Carson KA, Grossman SA, Burt Nabors L, Mikkelsen T, Lesser G, Rosenfeld S, Desideri S, Olson JJ (2010) Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol 100:95-103. doi:10.1007/s11060-010-0143-7
29. Rao SK, Edwards J, Joshi AD, Siu IM, Riggins GJ (2010) A survey of glioblastoma genomic amplifications and deletions. J Neurooncol 96:169-179. doi:10.1007/s11060-009-9959-4
30. Raychaudhuri B, Han Y, Lu T, Vogelbaum MA (2007) Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype. J Neurooncol 85:39-47. doi:10.1007/s11060-007-9390-7
31. Robe PA, Bentires-Alj M, Bonif M, Rogister B, Deprez M, Haddada H, Khac MT, Jolois O, Erkmen K, Merville MP, Black PM, Bours V (2004) In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res 10:5595-5603. doi:10.1158/1078-0432.CCR-03-0392
32. Roesler R, Brunetto AT, Abujamra AL, de Farias CB, Brunetto AL, Schwartsmann G (2010) Current and emerging molecular targets in glioma. Expert Rev Anticancer Ther 10:1735-1751. doi:10.1586/era.10.167
33. Roth P, Kissel M, Herrmann C, Eisele G, Leban J, Weller M, Schmidt F (2009) SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo. Clin Cancer Res 15:6609-6618. doi:10.1158/1078-0432.CCR-09-0548
34. Russo A, Bronte G, Fulfaro F, Cicero G, Adamo V, Gebbia N, Rizzo S (2010) Bortezomib: a new pro-apoptotic agent in cancer treatment. Curr Cancer Drug Targets 10:55-67
35. Soni D, King JA, Kaye AH, Hovens CM (2005) Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge. J Clin Neurosci 12:1-5. doi:10.1016/j.jocn.2004.04.001
36. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011-1018. doi:10.1016/S0140-6736(02)08091-1
37. Thaker NG, Zhang F, McDonald PR, Shun TY, Lewen MD, Pollack IF, Lazo JS (2009) Identification of survival genes in human glioblastoma cells by small interfering RNA screening. Mol Pharmacol 76:1246-1255. doi:10.1124/mol.109. 058024
38. Vaziri SA, Hill J, Chikamori K, Grabowski DR, Takigawa N, Chawla-Sarkar M, Rybicki LR, Gudkov AV, Mekhail T, Bukowski RM, Ganapathi MK, Ganapathi R (2005) Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3-sigma and survivin. Mol Cancer Ther 4:1880-1890. doi:10.1158/1535-7163. MCT-05-0222
39. Wagenknecht B, Hermisson M, Eitel K, Weller M (1999) Protea-some inhibitors induce p53/p21-independent apoptosis in human glioma cells. Cell Physiol Biochem 9:117-125. doi:10.1159/000016308
40. Wagenknecht B, Hermisson M, Groscurth P, Liston P, Krammer PH, Weller M (2000) Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release. J Neurochem 75:2288-2297. doi:10.1046/j.1471-4159.2000.0752288.x
41. Wang H, Wang H, Zhang W, Huang HJ, Liao WS, Fuller GN (2004) Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest 84:941-951. doi:10.1038/labinvest.3700123
42. Weaver KD, Yeyeodu S, Cusack JC, Baldwin AS, Ewend MG (2003) Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 61:187-196. doi:10.1023/A:1022554824129
43. Yang Y, Shao N, Luo G, Li L, Zheng L, Nilsson-Ehle P, Xu N (2010) Mutations of PTEN gene in gliomas correlate to tumor differentiation and short-term survival rate. Anticancer Res 30:981-985
44. Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL, Koeffler HP (2005) Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24:344-354. doi:10.1038/sj.onc.1208225
45. Zanotto-Filho A, Delgado-Cañedo A, Schröder R, Becker M, Klamt F, Moreira JC (2010) The pharmacological NFkappaB inhibitors BAY117082 and MG132 induce cell arrest and apo-ptosis in leukemia cells through ROS-mitochondria pathway activation. Cancer Lett 288:192-203. doi:10.1016/j.canlet.2009. 06.038
46. Zanotto-Filho A, Gelain DP, Schröder R, Souza LF, Pasquali MA, Klamt F, Moreira JCF (2009) The NFkappaB-mediated control of RS and JNK signaling in vitamin A-treated cells: duration of JNK-AP-1 pathway activation may determine cell death or proliferation. Bio-chem Pharmacol 77:1291-1301. doi:10.1016/j.bcp.2008.12.010